肾素-血管紧张素-醛固酮系统阻滞剂在Alport综合征患者中的有效性:系统评价与荟萃分析
该系统评价与荟萃分析纳入8项研究共1182例Alport综合征患者,比较RAAS阻滞剂与非RAAS治疗对疾病进展的影响。结果显示RAAS阻滞剂可降低进展至终末期肾病的风险(HR 0.33,95%CI 0.24-0.45),各遗传类型均获益,且早期开始治疗获益更明显。
要点
- RAAS阻滞剂降低Alport综合征进展至ESKD风险(4项研究,HR 0.33,95%CI 0.24-0.45,中等确定性证据)。
- 男性X连锁Alport综合征HR 0.32(95%CI 0.22-0.48),常染色体隐性Alport综合征HR 0.25(95%CI 0.10-0.62)。
- 女性X连锁及常染色体显性Alport综合征HR 0.40(95%CI 0.21-0.75),获益随治疗起始疾病阶段呈现梯度。
核心结论
- 该荟萃分析提示,RAAS阻滞剂可考虑作为任何遗传类型Alport综合征延缓ESKD的特定治疗,尤其在疾病早期阶段,且后续更有效的治疗建议在此基础上叠加。
研究设计与样本
- 系统评价与荟萃分析,纳入8项已发表研究,共1182例Alport综合征患者,比较接受RAAS阻滞剂与非RAAS治疗者的疾病进展相关结局,采用随机效应模型进行荟萃分析。
主要发现
- 与非RAAS治疗相比,RAAS阻滞剂可降低进展至终末期肾病的风险(4项研究,HR 0.33,95%CI 0.24-0.45,中等确定性证据)。
- 按遗传类型分层后获益相似:男性X连锁Alport综合征HR 0.32(95%CI 0.22-0.48),常染色体隐性Alport综合征HR 0.25(95%CI 0.10-0.62),女性X连锁及常染色体显性Alport综合征HR 0.40(95%CI 0.21-0.75)。
- RAAS阻滞剂的获益随治疗起始时疾病阶段呈现明显梯度。
关键数值与推荐
- 总体偏倚风险为低至中等,采用Cochrane偏倚风险工具、纽卡斯尔-渥太华量表和GRADE方法评估证据确定性。
- 进展至ESKD的合并HR 0.33(95%CI 0.24-0.45),证据确定性为中等。
临床怎么用
- 作者认为,RAAS阻滞剂可考虑作为任何遗传类型Alport综合征延缓ESKD的特定治疗,尤其在疾病早期阶段。
- 作者建议,后续更有效的治疗应在此基础上叠加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although renin-angiotensin-aldosterone system (RAAS) blockers have been considered the primary treatment for patients with Alport syndrome (AS) for a decade, there is no comprehensive review with evidence-based analysis evaluating the effectiveness of RAAS blockers in AS. METHODS: A systematic review and meta-analysis was performed of published studies that compared outcomes related to disease progression between patients with AS receiving RAAS blockers with those taking non-RAAS treatment. Outcomes were meta-analyzed using the random effects models. Cochrane risk-of-bias, Newcastle-Ottawa Scale and Grading of Recommendations Assessment, Development and Evaluation methodology (GRADE) assessment determined the certainty of evidence. RESULTS: A total of eight studies (1182 patients) were included in the analysis. Overall, the risk of bias was low to moderate. Compared with non-RAAS treatment, RAAS blockers could reduce the rate of progression to end-stage kidney disease (ESKD) [four studies; hazard ratio (HR) 0.33, 95% confidence interval (CI) 0.24-0.45; moderate certainty evidence]. After stratified by genetic types, a similar benefit was detected: male X-linked AS (XLAS) (HR 0.32, 95% CI 0.22-0.48), autosomal recessive AS (HR 0.25, 95% CI 0.10-0.62), female XLAS and autosomal dominant AS (HR 0.40, 95% CI 0.21-0.75). In addition, RAAS blockers showed a clear gradient of benefit depending on the stage of disease at the initiation of treatment. CONCLUSION: This meta-analysis suggested that RAAS blockers could be considered as a specific therapy to delay of ESKD for AS with any genetic type, especially at the early stage of the disease, and every further more-effective therapy would be advised to be applied on top of this standard of care.
引用
- Zeng M, Di H, Liang J, et al. Effectiveness of renin-angiotensin-aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis. Nephrol Dial Transplant. 2023. PMID: 37218713. doi:10.1093/ndt/gfad105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。